Finance
Staar Surgical to Reject Alcon Takeover Bid After Failing to Win Shareholder Backing
Published by Global Banking & Finance Review®
Posted on January 6, 2026
2 min readLast updated: January 20, 2026
Add as preferred source on GoogleQuick Summary
Staar Surgical will end its merger with Alcon due to insufficient shareholder support, despite an increased $1.6B offer.
Staar Surgical to End Alcon Merger After Shareholder Vote
By Mariam Sunny
Jan 6 (Reuters) - STAAR Surgical said on Tuesday it plans to terminate its merger agreement with Swiss eyecare giant Alcon after failing to secure enough shareholder votes to approve the deal, sending its shares down more than 12%.
The vote follows a bitter standoff between Staar's board and key shareholders, even as Alcon stepped up efforts to push the takeover across the finish line.
Alcon had last month made a new offer worth $1.6 billion for Staar, up from its original offer of $1.5 billion.
"We respect the outcome of the vote and look forward to working collaboratively with shareholders to ensure the best possible outcome for STAAR as a standalone company," CEO Stephen Farrell said.
Broadwood Partners, Staar's biggest shareholder with nearly 30.2% stake, had actively opposed Alcon's initial offer, saying it undervalues the business and reflects a flawed sale process.
"As STAAR's largest shareholder, we are confident in the company's standalone prospects and committed to helping STAAR realize its abundant potential for the benefit of all shareholders," Broadwood's founder and president, Neal Bradsher, said on Tuesday.
Staar, which produces and markets implantable eye lenses, has struggled with declining revenue and a collapse in sales in China.
"Part of how Staar emerges from this period depends on what existing or new management will want to do with the company but also the health of its broader end-markets (including China)", BTIG analyst Ryan Zimmerman said.
Shares are "unlikely to see much, if any bid, as investors have limited reason to want to own Staar until clarity on the company emerges," he said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas and Sahal Muhammed)
Key Takeaways
- •Staar Surgical to terminate merger with Alcon.
- •Shareholder votes insufficient to approve the deal.
- •Alcon's offer increased from $1.5B to $1.6B.
- •Broadwood Partners opposed the initial offer.
- •Staar faces challenges in revenue and China sales.
Frequently Asked Questions about Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing
1What is a merger?
A merger is a business combination where two companies join to form a new entity, often to enhance competitiveness, increase market share, or achieve synergies.
2What is shareholder value?
Shareholder value refers to the financial worth that shareholders gain from owning shares in a company, typically measured by stock price appreciation and dividends.
3What is corporate governance?
Corporate governance is the system of rules, practices, and processes by which a company is directed and controlled, focusing on the interests of stakeholders.
4What is a takeover bid?
A takeover bid is an offer made by an individual or company to purchase another company, often at a premium over the current market price.
5What is investment?
Investment is the allocation of resources, usually money, to generate income or profit, often through purchasing assets like stocks, bonds, or real estate.